Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regdanvimab
- Development stage
- Phase 3
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Regdanvimab is a recombinant human IgG1 monoclonal antibody developed for the treatment of COVID-19. It specifically targets the receptor binding domain (RBD) of the spike protein of SARS-CoV-2, blocking its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. By preventing this interaction, regdanvimab neutralizes SARS-CoV-2 and inhibits viral entry and replication within human cells. The drug is administered as a single intravenous infusion, typically within seven days of symptom onset in patients at risk for severe disease progression. Regdanvimab has been approved in South Korea and authorized in the European Union for adults with COVID-19 who do not require supplemental oxygen but are at increased risk of developing severe disease[1][3][4][5].
- Brand names
- Regkirona
- Other names
- regdanvimab
02
Targets
RBM (SARS-CoV-2 spike receptor-binding motif)
Beyond the preview
Go deeper on regdanvimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regdanvimab.